galanthamine 's ability to reverse cognitive deficits induced by nbm lesions and its comparatively long half-life suggest that it may be effective in treating the central cholinergic deficits in alzheimer 's disease patients .
C0016967
galanthamine 's
C0002395
alzheimer 's disease